Description:

Halaven (Eribulin) is an anticancer medication used for the treatment of metastatic breast cancer. It belongs to a class of drugs known as microtubule inhibitors and is specifically classified as a non-taxane microtubule dynamics inhibitor.

Indications:

Halaven (Eribulin) is indicated for the treatment of:

1. Metastatic Breast Cancer: It is used in patients with locally advanced or metastatic breast cancer who have previously received at least two chemotherapeutic regimens, including an anthracycline and a taxane, in either the adjuvant or metastatic setting.

How It Works:

Eribulin inhibits the growth phase of microtubules, essential components of the cell’s structural framework. By doing so, it disrupts the normal process of cell division, leading to cell cycle arrest and apoptosis (programmed cell death) in cancer cells.

Dosage and Administration:

The dosage and administration of Halaven are determined by a healthcare professional based on the patient’s condition, response to previous treatments, and overall health. It is administered as an intravenous (IV) infusion.

Possible Side Effects:

Common side effects of Halaven may include fatigue, nausea, alopecia (hair loss), neutropenia (low white blood cell count), and peripheral neuropathy. Other side effects can occur, and patients are closely monitored during and after treatment.

Warnings and Precautions:

1. Bone Marrow Suppression: Eribulin can cause myelosuppression, including neutropenia. Regular blood cell count monitoring is essential.
2. Peripheral Neuropathy: Peripheral neuropathy, which can cause tingling or numbness in the extremities, may occur. Monitoring for symptoms and dose adjustments may be necessary.
3. Hepatic Impairment: Eribulin is metabolized in the liver, and caution is advised in patients with hepatic impairment.
4. Pregnancy and Breastfeeding: Halaven can cause fetal harm, and its use is generally avoided during pregnancy. Breastfeeding is not recommended during treatment.
5. QT Prolongation: Eribulin may prolong the QT interval, and caution is advised in patients with a history of QT prolongation.
6. Pre-existing Neurological Conditions: Caution is recommended in patients with pre-existing neurological conditions.

Halaven is a prescription medication, and its use should be guided by a healthcare professional experienced in the administration of anticancer therapies. Patients should discuss any potential concerns or side effects with their healthcare provider. Always follow the prescribed dosage and administration instructions.